Moleculin Biotech is trading at $7.60, down -12.94% in pre-market; available coverage identified no clear company-specific announcement explaining the decline. - Latest verified company news, dated November 4, reported interim Annamycin trial remission rates of 43% and 36% in treatment arms, versus 12% for placebo. - The monitoring committee recommended continuing the study unchanged; that earlier positive update does not explain the November 6 pre-market decline. - Supplied market indicators are mixed, offering no clear broader-market explanation.